Tolerance and clinical response to SGL2 inhibitors in Fabry disease

被引：0
|
作者：
Mattig, I. [1 ]
Bonnekoh, C. [2 ]
Zirkelbach, B. [1 ]
Stangl, K. [1 ]
Hindricks, G. [1 ]
Knebel, F. [3 ]
Canaan-Kuehl, S. [2 ]
Spethmann, S. [1 ]
机构：
[1] Charite, Deutsch Herzzentrum Charite, Berlin, Germany
[2] Charite, Berlin, Germany
[3] Sana Klinikum Berlin Lichtenberg, Cardiol, Berlin, Germany
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2024年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：236 / 236
页数：1
相关论文
共 50 条
  • [41] Response to: Urine bikunin and kidney involvement in Fabry disease
    Chimenz, Roberto
    Lacquaniti, Antonio
    PEDIATRIC NEPHROLOGY, 2022, 37 (08) : 1935 - 1935
  • [42] Response to: Urine bikunin and kidney involvement in Fabry disease
    Roberto Chimenz
    Antonio Lacquaniti
    Pediatric Nephrology, 2022, 37 : 1935 - 1935
  • [43] Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
    Mehta, A
    Ricci, R
    Widmer, U
    Dehout, F
    de Lorenzo, AG
    Kampmann, C
    Linhart, A
    Sunder-Plassmann, G
    Ries, M
    Beck, M
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (03) : 236 - 242
  • [44] IDENTIFICATION OF FABRY DISEASE IN 2 BROTHERS
    BEYER, E
    DJATLOVITSKAYA, E
    ZAIRATYANTS, O
    BERESTOVA, A
    MENDELSON, M
    BROOK, E
    WIEDERSCHAIN, G
    JOURNAL OF INHERITED METABOLIC DISEASE, 1990, 13 (02) : 230 - 231
  • [45] Favorable Response to Type 2 Inhibitors in Patients With Darier Disease
    Binjadeed, Hessah
    Huang, Han Zhang
    Joly-Chevrier, Maxine
    Javed, Gazal
    Netchiporouk, Elena
    JAMA DERMATOLOGY, 2024, 160 (09) : 1007 - 1009
  • [46] Clinical response to Enzyme replacement therapy (ERT) with agalsidase beta in a pediatric patient with Fabry disease.
    Peterschmitt, MJ
    Della Giovanna, P
    Lago, NR
    Repetto, HA
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 454 - 454
  • [47] FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease
    Mignani, Renzo
    Pieruzzi, Federico
    Berri, Francesco
    Burlina, Alessandro
    Chinea, Benito
    Gallieni, Maurizio
    Pieroni, Maurizio
    Salviati, Alessandro
    Spada, Marco
    CLINICAL KIDNEY JOURNAL, 2016, 9 (05): : 739 - 747
  • [48] Clinical benefits of early treatment with fabrazyme in Fabry disease
    Waldek, S.
    Banikazemi, M.
    Bultas, J.
    Wilcox, W.
    Whitley, C.
    McDonald, M.
    Finkel, R.
    Packman, S.
    Bichet, D.
    Warnock, D.
    Brenner, B.
    Desnick, R.
    CLINICAL THERAPEUTICS, 2007, 29 : S29 - S29
  • [49] Fabry disease: Clinical and pathologic manifestations in renal involvement
    Lin, C. -Y.
    CLINICAL THERAPEUTICS, 2008, 30 : S56 - S57
  • [50] CLINICAL MANIFESTATIONS AND PREVALENCE OF FABRY DISEASE IN HEMODIALYSIS PATIENTS
    Moiseev, Sergey
    Namazova-Baranova, Leyla
    Savostyanov, Kirill
    Bulanov, Nikolay
    Karovaikina, Ekaterina
    Moiseev, Aleksey
    Fomin, Viktor
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
12345